Neose Files IND for NE-180 for the Treatment of Anemia
HORSHAM, Pa., June 23 /PRNewswire-FirstCall/ -- Neose Technologies, Inc. (NASDAQ:NTEC) today announced that it has submitted an investigational new drug
application (IND) to the U.S. Food and Drug Administration (FDA) for NE- 180.
NE-180 is the company's long-acting, GlycoPEGylated erythropoietin for the
treatment of chemotherapy-induced anemia. Pending clearance by the FDA, the
Company expects to initiate its Phase I clinical trial in the third quarter.
About Neose Technologies, Inc.
Neose is a biopharmaceutical company using its proprietary enzymatic
technologies to develop improved drugs, focusing primarily on therapeutic
proteins. Neose uses its GlycoAdvance(R) and GlycoPEGylation(TM) technologies
to develop improved versions of drugs with proven safety and efficacy. Neose
intends to apply its technologies to products it is developing on its own and
to products it co-develops and co-owns with others. It also expects to make
its technologies available, through strategic partnerships, to improve the
products of other parties. Neose's first two proprietary candidates are NE-
180 and GlycoPEG-GCSF, a long-acting version of granulocyte colony stimulating
factor (G-CSF).
CONTACTS: Neose Technologies, Inc.
A. Brian Davis
Sr. Vice President and Chief Financial Officer
(215) 315-9000 Barbara Krauter
Manager, Investor Relations
(215) 315-9004 For more information, please visit http://www.neose.com/.
Neose "Safe Harbor" Statement under the Private Securities Litigation Reform
Act of 1995: Statements in this press release regarding our business that are
not historical facts are "forward-looking statements" that involve risks and
uncertainties, including without limitation the risk that we will not receive
clearance from the FDA to initiate a Phase I clinical trial. For a discussion
of these risks and uncertainties, any of which could cause our actual results
to differ from those contained in the forward-looking statement, see the
section of Neose's Annual Report on Form 10-K for the year ended December 31,
2004, entitled "Factors Affecting the Company's Prospects" and discussions of
potential risks and uncertainties in Neose's subsequent filings with the SEC. DATASOURCE: Neose Technologies, Inc.
CONTACT: A. Brian Davis, Sr. Vice President and Chief Financial Officer, +1-215-315-9000, or Barbara Krauter, Manager, Investor Relations, +1-215-315-9004, both of Neose Technologies, Inc.
Web site: http://www.neose.com/
|